AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting. Roche has ...

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena. Top-line results from the CLL14 ...

AbbVie Inc. ABBV reported first-quarter 2025 adjusted earnings per share (EPS) of $2.46, which beat the Zacks Consensus ...

With a market cap of $309.7 billion, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company, engaged in the ...

Despite Imbruvica's 7% decline, the oncology portfolio grew 11% through Venclexta and Elahere's strong performance. The neuroscience segment grew 16.6%, while aesthetics remained stable despite ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...